Literature DB >> 3008880

[Detection of the pro-opiomelanocortin peptide fragments--beta-endorphin and ACTH--in the adrenals of rats and mice by immunohistochemistry].

V A Arefolov, A D Dmitriev, A V Tennov, A V Val'dman.   

Abstract

Independent peptide fragments of pro-opiomelanocortin molecule, beta-endorphin and ACTH, have been detected immunohistochemically in the adrenal glands of rats and mice. Immunoreactive beta-endorphin and ACTH have been revealed in the adrenal medulla and reticular zone of the adrenal cortex. beta-endorphin and ACTH distribution patterns in adrenal sections were identical, which is indicative of the linked synthesis of these peptides in the adrenal gland. The data obtained suggest the existence of pituitary-independent mechanisms regulating corticosteroidogenesis in the adrenal gland, involving adrenal pro-opiomelanocortin fragments.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008880

Source DB:  PubMed          Journal:  Biull Eksp Biol Med        ISSN: 0365-9615


  4 in total

1.  Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus.

Authors:  Septimiu Vele; Sofiya Milman; Harry Shamoon; Ilan Gabriely
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

2.  Opioid receptor blockade prevents exercise-associated autonomic failure in humans.

Authors:  Sofiya Milman; James Leu; Harry Shamoon; Septimiu Vele; Ilan Gabriely
Journal:  Diabetes       Date:  2012-04-20       Impact factor: 9.461

3.  Mediation of Endogenous β-Endorphin in the Plasma Glucose-Lowering Action of Herbal Products Observed in Type 1-Like Diabetic Rats.

Authors:  I M Liu; J T Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-19       Impact factor: 2.629

4.  Mediation of Endogenous beta-endorphin by Tetrandrine to Lower Plasma Glucose in Streptozotocin-induced Diabetic Rats.

Authors:  Jen-Hao Hsu; Yang-Chang Wu; Shorong-Shii Liou; I -Min Liu; Lee-Wen Huang; Juei-Tang Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2004-09-01       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.